Compare DuPont de Nemours Inc (DD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Sana Biotechnology Inc — how do they compare? DuPont de Nemours Inc trades at $144.49 (market cap $19.51B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: DuPont de Nemours Inc is far larger — about 17.3× Sana Biotechnology Inc's market cap, and DuPont de Nemours Inc pays a 1.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DD | SANA | |
|---|---|---|
Market Cap | $19.51B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $5.92 |
52-Week Low | $90.24 | $2.68 |
Enterprise Value | $20.90B | $1.05B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $141.56, down 0.65% over the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and aerospace demand, leading to a raised full-year 2026 outlook. The stock exhibits a high P/E ratio of 62.01, reflecting growth expectations, while net income margin remains thin at 0.79%.
Outlook is positive due to earnings momentum and strategic initiatives in water treatment and lithium extraction, but risks include legal settlements over PFAS chemicals and volatile cash flows. With a consensus price target of $232.80 implying significant upside, the stock offers growth potential tempered by execution and regulatory challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
